CUSIP 77313F106 · who reports it, how much, and how much it matters to them
23 of the 720 hedge fund managers we track reported shares of Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) on Form 13F for 30 June 2026. Between them they reported USD 129m. The largest position belongs to RTW Investments, at USD 60m. The manager with the most riding on it is Newtyn Management, where it is 1.7% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | RTW Investments2 funds on PPLI.com | USD 60m | 0.5% |
| 2 | Marshall Wace LLP84 funds on PPLI.com | USD 14m | 0.0% |
| 3 | Millennium Management6 funds on PPLI.com | USD 14m | 0.0% |
| 4 | Newtyn Management3 funds on PPLI.com | USD 14m | 1.7% |
| 5 | Maverick Capital20 funds on PPLI.com | USD 13m | 0.1% |
| 6 | D. E. Shaw & Co.15 funds on PPLI.com | USD 3.3m | 0.0% |
| 7 | Renaissance Technologies13 funds on PPLI.com | USD 2.7m | 0.0% |
| 8 | POINT72 Asset Management17 funds on PPLI.com | USD 2.3m | 0.0% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 1.1m | 0.0% |
| 10 | M28 Capital Management1 fund on PPLI.com | USD 721,000 | 1.5% |
| 11 | Squarepoint Ops7 funds on PPLI.com | USD 620,000 | 0.0% |
| 12 | Jain Global1 fund on PPLI.com | USD 461,000 | 0.0% |
| 13 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 378,000 | 0.0% |
| 14 | Boothbay Fund Management2 funds on PPLI.com | USD 324,000 | 0.0% |
| 15 | Balyasny Asset Management25 funds on PPLI.com | USD 322,000 | 0.0% |
| 16 | Weiss Asset Management5 funds on PPLI.com | USD 294,000 | 0.0% |
| 17 | Lion Point Capital1 fund on PPLI.com | USD 294,000 | 1.4% |
| 18 | Engineers Gate Manager1 fund on PPLI.com | USD 245,000 | 0.0% |
| 19 | Citadel Advisors32 funds on PPLI.com | USD 243,000 | 0.0% |
| 20 | Walleye Capital8 funds on PPLI.com | USD 207,000 | 0.0% |
| 21 | Tudor Investment Corporation10 funds on PPLI.com | USD 173,000 | 0.0% |
| 22 | Voleon Capital Management13 funds on PPLI.com | USD 111,000 | 0.0% |
| 23 | Exoduspoint Capital Management7 funds on PPLI.com | USD 63,732 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Newtyn Management | USD 14m | 1.7% |
| 2 | M28 Capital Management | USD 721,000 | 1.5% |
| 3 | Lion Point Capital | USD 294,000 | 1.4% |
| 4 | RTW Investments | USD 60m | 0.5% |
| 5 | Maverick Capital | USD 13m | 0.1% |
| 6 | Marshall Wace LLP | USD 14m | 0.0% |
| 7 | Millennium Management | USD 14m | 0.0% |
| 8 | Renaissance Technologies | USD 2.7m | 0.0% |
| 9 | Boothbay Fund Management | USD 324,000 | 0.0% |
| 10 | POINT72 Asset Management | USD 2.3m | 0.0% |
Rocket Pharmaceuticals, Inc. trades under the symbol RCKT on the Nasdaq. Its CUSIP, the code used on Form 13F, is 77313F106.
23 of the 720 hedge fund managers PPLI.com tracks reported Rocket Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by RTW Investments (USD 60m), Marshall Wace LLP (USD 14m), Millennium Management (USD 14m), Newtyn Management (USD 14m) and Maverick Capital (USD 13m).
23 managers in our coverage reported it, and between them they run 338 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Newtyn Management, where the position was 1.7% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Rocket Pharmaceuticals, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.